Monday, October 15, 2007

Pri-Med East (Boston) 2007 Round-Up

Pri-Med is a medical conference geared towards folks involved in the primary care medicine of healthcare services.These could include small to large group practices to hospitals in a multi-specialty environment.



I generally do not attend talks for 2 reasons, (a) the pure-play clinical talks are not of interest to me and if they were, as I am not a physician I would not gain much out of it; (b) the action and the real answers are on the trade floor. Most often, talks for subjects that interest me are at a very primary level in such conferences.

5 years ago, this conference had no tech companies. Now, there were at least 35 tech vendors from gadgets to software to hardware to services. 2007 had a modest drop in the number of such vendors compared to 2006. This was mostly in the software space because of consolidations, change of focus for some of these firms and the now expensive real-estate to advertise and have a booth compared to previous years.

I spent most of my time talking to EMR (electronic medical records) companies like Allscripts, MediNotes, Cerner, McKesson, GE Medical, HCS, etc. I was disappointed in some of their representatives as either they knew only about their product and were clueless about their overall product release strategy or were generally clueless about the product once I started asking detailed questions. Some of them proudly talking about how they jumped ship. One would think that a company would at the very least put folks who know what they are doing as their representatives.

Further on the EMR's, I did ask the classic question of how each of them were different than other and no one really had a good answer on defensibility. Some of the systems I liked were from HCS and Catalis and folks like GE, Cerner and Allscripts, in my opinion, were at the bottom of the barrel. Maybe my standards are high, which they should be - given we are talking about 3rd generation systems in this domain.

The pharma folks did and always do a great job at company and product representation with much less obnoxious display of raw cash power in the kind of things they were giving away. It came as a welcome change for many ethically driven physicians.

Innovation: There was not much on the software side of the business, as I had expected. The EMR's are still in the "late 90's" stage of user intuitiveness, which is not entirely their fault given the massive complexities behind delivering even a resonably tight system. There were no start-ups that are truely changing some of the business models, neither was there any representation from GoogleHealth or Microsoft's HealthVault group. My take is that it though it may be a bit early for some of these folks to come, it would have been worth showcasing whats in the coming. Overall, disappointed and nothing new going on.

I did not spend anytime at the pharmas but the general sense was big on marketing low on evidence compared to last year. Again, a disappointment.

The real innovators however, were the large academic medical centers like Beth Israel Deaconess who had a modest booth but some incredible things to talk about.

Trends: The software folks, almost all of them, seem to either have some sort of a patient portal or have already launched one. The trend is in its 1st generation phase and will take a while to be truely integrated with all the modealities like labs, radiology, referral management, appointments, etc. Currently, from what I saw, the functionas and interface were in their infancy. Again, some of the academic centers were way ahead of the curve.

The device companies were hugely popular with the whole unregulated "medispa" speil. This is one of those industries that have grown to be a $6Billion+ capitalization since 2002 and continues to grow. Several of them were the usual suspets with a few "just seen on TV" types I'd like to call fly-by-night operators. What surprised me that they were targetting primary care physicians from a revenue upsel model.

Some of the pharma based device companies were showcasing several devices geared towards the self-use market.

I did see a 12 Megapixel Digital Camera with some incredible functions under $350! And I heard that the talks were good. I would not be inclined to go to Pri-Med next year unless the vendor list changes.

Labels:


Read more!

Friday, October 05, 2007

Harvard Entrepreneurship Forum Update

I am writing to you on behalf of the Harvard College Entrepreneurship Forum (HCEF), a new and rapidly growing organization devoted to promoting the spirit of entrepreneurship on the Harvard campus, and to helping students channel their creativity towards successful enterprise. This community is made up of over 200 of the most talented and creative Harvard undergraduates, and they receive widespread publicity for initiatives such as well-attended mixers, idea generation competitions and the Harvard Business Plan Competition. Most recently, they were featured in the Boston Globe Sunday Magazine as part of a feature article on student entrepreneurship.

As they enter in their second year, several of their best-known initiatives - namely the Business Plan Competition, Summer Fellowships Program, and Term-Time Startups Grants - are seeking support from individuals and corporations interested in promoting entrepreneurship on the Harvard campus. Sponsors would be invited to all of their high-profile events, credited in press releases, and given the opportunity to regularly interact with our thriving entrepreneurial community.
There have been a few successful commercial launches from this club, some already profitable companies.

If you have any questions, or would like further details about their 2007-2008 sponsorship opportunities, please contact me or Mike at the below email / tel.

Sincerely,

Michael Segal, Co-President,
msegal@fas.harvard. edu (215) 681-9328
__________________________________


Read more!

FOREIGN VENTURE CAPITAL INVESTMENT IN INDIA

Folks wanting to start a fund and invest in India will find this very functional article written by an old friend of mine from college, Ashish Bhakta, very useful. Ashish has been practicing corporate law within large to mid-sized venture / private equity deals in India and Europe.

- - - - - - - - - -

Introduction


The Indian capital market regulator, the Securities & Exchange Board of India (“SEBI”) is the single window clearance for both domestic and foreign venture capital funds (“VC Funds”) proposing to invest in India. VC Funds, operating in certain sectors, which are registered with SEBI, are entitled to tax benefits subject to certain conditions. However, in order to avail of these benefits, registration with SEBI is critical.

Foreign VC funds: Is registration MANDATORY?

SEBI has issued the Foreign Venture Capital Investor Regulations, 2000 (“the Regulations”) which apply to Foreign Venture Capital Investors (“FVCI”) incorporated and established outside India and which propose to invest in India.

Earlier, FVCIs avoided registering themselves with SEBI, due to the extremely confusing regulatory and tax position. FVCIs preferred to operate from outside India, usually through a liaison office in India. This is no longer the case following the enactment of the Regulations as also the amendment to the Indian Income Tax Act, 1961 (“IT Act”). Apart from clear advantages of registration, a view has been expressed that it is mandatory for an FVCI proposing to make investments in unlisted Indian companies to register with SEBI under the Regulations.

This view is based on Section 12(1B) of the SEBI Act, 1992 which provides that no person shall sponsor or carry on any venture capital fund, unless he obtains a certificate of registration from SEBI in accordance with the Regulations. Failure to so register may amount to a contravention of the provisions of Section 12(1B) of the SEBI Act, 1992, which can lead to penal consequences.

This view proceeds on the assumption that a distinction must be made between a non-resident making a Foreign Direct Investment (“FDI”) and an FVCI. This distinction can be established from the nature of the agreements entered into by such foreign investor with the Indian investee companies and its promoters as also whether such foreign investor otherwise carries on the business of being a venture capital fund outside India.

This contention is reinforced with India’s central bank, the Reserve Bank of India (“RBI”), recently amending the Foreign Exchange Management (Transfer or Issue of Security by a Person Resident outside India) Regulations, 2000 (“the Amendment”), to specifically bring within its fold investments by a SEBI registered FVCI in a domestic, SEBI registered venture capital fund (“Domestic Fund”) or an unlisted Indian company. The effect of the Amendment is that such investment will no longer be regarded as FDI, but as a separate category of investment. The advantage of such treatment is, that shares issued by unlisted Indian companies to an FVCI shall not be subject to compliance with the usual pricing guidelines, and the FVCI may acquire or purchase the shares issued by unlisted Indian companies at a price that is mutually agreed between the buyer and the seller/issuer.

The major advantage, of registration is that, under the IT Act, several tax benefits are conferred upon the FCVI, provided the FVCI is investing in the sectors specified below. Registration is evidenced by a certificate issued by SEBI after taking into consideration inter alia the track record, professional competence, financial soundness, experience, general reputation of fairness and integrity of the FVCI.

What does registration entail? :
There is no minimum capitalization requirement for being registered as an FVCI. It can invest either in a Domestic Fund or in a domestic company whose shares are not listed on a recognized stock exchange in India (it does not matter if its shares are listed on a stock exchange outside India such as the NASDAQ or the NYSE) and is not engaged in any activity except real estate, non-banking financial services or gold financing (“a venture capital undertaking”). All investment made or to be made by an FVCI shall be subject to the following conditions:
It shall disclose the investment strategy;
It shall not invest more than 25% corpus of the fund in one venture capital undertaking;
It shall make investments in the venture capital under-taking as enumerated below:
at least 75% of the investible funds shall be invested in unlisted equity shares or equity linked instruments
o Not more than 25% of the investible funds may be invested by way of
subscription to initial offer of a venture capital undertaking whose shares are proposed to be listed subject to lock-in period of one year;
debt or debt instrument of a venture capital undertaking in which the foreign venture capital investor has already made an investment by way of equity.
The Regulations require an FVCI to appoint a domestic custodian as well as open a non-resident rupee or foreign currency account with a designated bank. Banks are allowed to offer forward cover (for hedging against forex risk) to FVCIs to the extent of their inward remittance.

Taxation of FVCI

Under Section 90(2) of the IT Act, a non-resident assessee based in a country with which India has a double taxation avoidance agreement (“DTA”), may opt to be taxed either under the IT Act or the DTA, whichever is more beneficial to him.

Under Section 10(23FB) of the IT Act, any income of a registered FVCI shall be exempt from income tax. The FVCI can carry on business in India through a permanent establishment in India, and yet its entire income would be tax-free. On the other hand, if the FVCI opts to be taxed under the DTA and it has a permanent establishment in India, its Indian income will not be tax free.

The tax exemption under section 10(23FB) has to be read with section 115U of the IT Act which confers a ‘pass-through’ status on SEBI registered Venture Funds. However, pursuant the Union Budget 2007, this ‘pass through’ status has been restricted to the following sectors:

  • nano-technology;
  • information technology relating to hardware and software development;
  • seed research and development;
  • bio-technology;
  • research and development of new chemical entities in the pharmaceutical sector;
  • production of bio-fuels;
  • building and operating composite hotel-cum-convention centres with seating capacity of more than three thousand;
  • dairy or poultry industry;
  • Infrastructure.

No tax shall be payable as tax on dividend and no tax deduction at source shall be made from income paid by a FVCI operating in these sectors.

However, any FVCI providing management, marketing, networking or any other services, may fall under the category of ‘taxable services’ under service tax regulations. In case of a FVCI having no office in India providing ‘taxable services’, the recipient of such services in India i.e. venture capital undertaking shall be liable to pay service tax.

Taxation of the Investor: Section 115U of the IT Act provides that investors in such funds would be liable to tax in respect of the income received by them from the FVCI in the same manner as it would have been, had the investors invested directly in the venture capital undertaking. In other words, income earned by an FVCI by way of dividend, interest or capital gains, upon distribution, would continue to retain the same character in the hands of its investors.

Nature of the income derived by an FVCI: This brings us to a question as to the nature of the income derived by an FVCI from its Indian investments. While dividend declared by an Indian company is tax free in the hands of any recipient, including an FVCI, the gains, an FVCI would make upon exit from an Indian investment, was so far regarded as capital gains. However, there are conflicting views as to whether profits made by a private equity fund/ venture capital fund should be taxed as business profits and not as capital gains .

Are non-resident investors in an FVCI, therefore, liable to pay Indian income-tax on what they receive from the FVCI as ‘business profits’, even though the FVCI itself does not have to pay any tax? Although Section 115 U begins with the words “Notwithstanding anything contained in any other provisions of this Act”, and it would override the normal provisions relating to taxability of individual items of income, it cannot override Section 90(2) relating to DTA provisions. India is a signatory to the Vienna Convention on the Law of Treaties and, therefore, tax treaties have a special status as compared to domestic tax legislation and would prevail unless there is an express specific domestic provision to override the treaty. In the present case, it does not appear to be the intention of the legislature that Section 115 U should override Section 90(2).

Accordingly, a non-resident investor in an FVCI, who receives dividend from the FVCI, is entitled to characterise the same as dividend under the DTA, by opting to be taxed under the DTA and not the IT Act. However, it is possible that the Indian tax authorities may contend that the investor is not entitled to the DTA benefit in view of Section 115 U and is liable to pay tax on business profits in India. Tax planning structures could be worked out to protect against such an eventuality, however remote it may be.

Taxing the ‘Carry’: Under the SEBI regulations relating to mutual funds, it is mandatory that a mutual fund must have a separate asset management company (“AMC”). However, the Regulations do not make this a mandatory requirement for an FVCI. This difference is critical from the viewpoint of tax in as much as while the income of an FVCI is tax free, the income of a domestic AMC is subject to 35.7% tax in India (foreign AMC - 48% tax). It is not advisable for an offshore AMC to render services to an FVCI by deploying its personnel to India for carrying out various activities such as validation of business plans, due diligence, etc., as the Indian tax authorities may contend that such AMC is deemed to have a permanent establishment in India and liable to be taxed in India on such part of the ‘carry’ as is attributable to its operations in India.

Structuring FVCIs: On account of its favourable DTA with India, Mauritius has become a favourite jurisdiction for investing into India. An obvious question arises. If the FVCI is to avail of the total tax exemption under Section 10(23FB), why does it require to be incorporated in Mauritius or any other country with whom India has a favourable DTA. The answer is, that having regard to the legislative fickleness with which the IT Act is amended annually, even if the tax exemption provisions contained in Section 10(23FB) are withdrawn, the FVCI could then rely upon the provisions of the DTA, so that its income continues to be tax free. Thus, there is dual protection. Of course, in such an event, the FVCI cannot have a permanent establishment in India.

The FVCI can be incorporated as a Mauritius offshore company and will be a tax resident of Mauritius. This process is quick and user friendly. The second step is to register with SEBI as an FVCI. If the FVCI intends to have a place of business in India, under the Foreign Exchange Management (Establishment in India of Branch or Office or other place of Business) Regulations, 2000, it will require RBI approval.

Before investing in a Venture Capital undertaking, the FVCI shall have to apply to RBI, through SEBI, for permission. The manner in which these Regulations are drafted, it appears that the FVCI may have to obtain such permission on a case to case basis, every time it makes an investment. However, in practice, RBI may grant a general or blanket permission as in the case of Foreign Institutional Investors.

Conclusion: As is evident from the above analysis, there are still a couple of grey areas which require tax planning for FVCI and their investors. While SEBI efficiently handles registration, formal permissions under Exchange Control Laws are still required. However, the entire process of setting up an FVCI is much simpler now and can be completed in a time span of 90 days. The total tax exemption in certain sectors makes these investments very attractive indeed.

Article Authored and By:

Ashish Bhakta, Partner

Kanga & Co. - Advocates & Solicitors

Address: Readymoney Mansion 43, Veer Nariman Rd Fort Mumbai 400 001 INDIA

Tel: +91 (22). 663.32288

The views expressed are of his own and should not be construed as legal advise

Labels:


Read more!
Get Free Shots from Snap.com